Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease

Scandinavian Journal of Gastroenterology

Volumn 50, Issue 3, 2014, Pages 255-263

  Kvasnovsky, Charlotte L ^a   Aujla, Usman ^a   Bjarnason, Ingvar ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

COX 1; COX 2; Crohn's disease; Cyclooxygenase; Exacerbations; Indeterminate colitis; Inflammatory bowel disease; Nonsteroidal anti inflammatory drugs; Ulcerative colitis

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SULFONAMIDE; SULFONE;

ARTICLE; CASE CONTROL STUDY; CASE REPORT; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DISEASE EXACERBATION; DRUG EFFECT; HUMAN; INFLAMMATORY BOWEL DISEASE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RELAPSE; CHEMICALLY INDUCED; GASTROINTESTINAL TRACT; METABOLISM; PAIN; RECURRENT DISEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; OBSERVATIONAL STUDY AS TOPIC; PAIN; PYRAZOLES; PYRIDINES; RECURRENCE; SULFONAMIDES; SULFONES;

EID: 84922721257     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.966753     Document Type: Article

References (38)

1. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11.
2. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-706.
3. Levenstein S, Prantera C, Varvo V, Scribano ML, Andreoli A, Luzi C, et al. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol 2000;95:1213-20.
4. Soderholm JD, Yang PC, Ceponis P, Vohra A, Riddell R, Sherman PM, et al. Chronic stress induces mast celldependent bacterial adherence and initiates mucosal inflammation in rat intestine. Gastroenterology 2002;123:1099-108.
5. Rampton DS, Sladen GE. Relapse of ulcerative proctocolitis during treatment with NSAID. Postgrad Med J 1981;57:297-9.
6. Hey H, Schmedes A, Nielsen AA, Winding P, Gronbaek H. Effects of five different alcoholic drinks on patients with Crohn's disease. Scand J Gastroenterol 2007;42:968-72.
7. Miner PB Jr. Factors influencing the relapse of patients with inflammatory bowel disease. Am J Gastroenterol 1997;92:1S-4S.
8. Orchard TR, Thiygaraja S, Welsh KI, Wordsworth BP, Gaston JHS, Jewell DP. Clinical phenotype is related to HLA genotype in the peripheral arthropathies in inflammatory bowel disease. Gastroenterology 2000;118:274-8.
9. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998;42:387-91.
10. Campieri M, Franchi LGA, Bazzocchi G, Brignola C, Benatia B, Boccia S, et al. Prostaglandins, indomethacin and ulcerative colitis. Gastroenterology 1980;78:193.
11. Wolfe MM, Lichtenstein DR, Singh G. Gastro intestinal safety of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
12. Bjarnason I, Hayllar J, Macpherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine. Gastroenterology 1993;104:1832-47.
13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-12.
14. Rampton DS, Sladen GE. Prostaglandin synthesis inhibitors in ulcerative colitis: flurbiprofen compared with conventional treatment. Prostaglandins 1981;21:417-25.
15. Kaufman HJ, Taubin HL. NSAID activate quiescent inflammatory bowel disease. Ann Intern Med 1987;107:513-16.
16. Pearson DJ, Stones NA, Bentley SJ. Proctocolitis induced by salicylate and associated with asthma and recurrent nasal polyps. BMJ 1983;287:1675.
17. Walt RP, Hawkey CJ, Langman MJ. Colitis associated with non-steroidal anti-inflammatory drugs. BMJ 1984;288:238.
18. Rutherford D, Stockdill G, Hamer-Hodges DW,Ferguson A. Proctocolitis induced by salicylate. BMJ 1984;288:794.
19. Rampton DS, McNeil MI, Sarner M. Analgesic ingestion and other factors preceding relapse in ulcerative colitis. Gut 1983;24:187-9.
20. Evans JMM, McMahon AD, Murray FE, McDevitt DG, MacDonald TM. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997;40:619-22.
21. Bonner GF, Walczak M, Kitchen L, Bayona M. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol 2000;95:1946-8.
22. Bonner GF, Fakhri A, Vennamaneni SR. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis 2004;10:751-7.
23. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 2000;95:1949-54.
24. Meyer AM, Ramzan NN, Heigh RI, Leighton JA. Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci 2006;51:168-72.
25. Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol 2010;105:1994-2002.
26. Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:196-202.
27. Reinisch W, Miehsler W, Dejaco C, Harrer M, Waldhoer T, Lichtenberger C, et al. An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharmacol Ther 2003;17:1371-80.
28. Biancone L, Tosti C, Geremia A, Fina D, Petruzziello C, Emerenziani S, et al. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment Pharmacol Ther 2004;19:755-64.
29. Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebocontrolled, pilot study. Clin Gastroenterol Hepatol 2006;4:203-11.
30. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in infl ammatory bowel diseases. Am J Gastroenterol 2006;10:311-17.
31. Kvasnovsky CL, Papagrigoriadis S, Bjarnason I. Increased diverticular complications with NSAIDs and other medications: a systematic review and meta-analysis. Colorectal Dis 2014;16:O189-96.
32. Bjarnason I, Macpherson AJS, Somasundaram S, Teahon K. Non-steroidal anti-inflammatory drugs and Crohn's disease. In Scholmeric J, Kruis W, Goebbell H, Hohenberger W, Gross V, editors. Inflammatory bowel diseases: pathophysiology as basis of treatment. Falk Symposium No 67. Lancaster: Kluwer Academic Publishers; 1993. pp 208-22.
33. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607.
34. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501-23.
35. Grimes DA, Schulz KF. Cohort studies: marching towards outcomes. Lancet 2002;359:341-5.
36. Mann CJ. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J 2003;20:54-60.
37. Tibble J, Roseth A, Teahon K, Thjodleifsson B, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-13.
38. Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176-80.